Literature DB >> 14581248

Evaluation of walking capacity over time in 500 patients with intermittent claudication who underwent clinical treatment.

Nelson Wolosker1, Livio Nakano, Ruben Aizyn Rosoky, Pedro Puech-Leao.   

Abstract

BACKGROUND: The use of physical training in the treatment of intermittent claudication is well established. However, current data do not provide enough information about the prognosis for each case, and there are no data on how walking distances evolve over time with conservative treatment. The goal of this study was to evaluate improvement in walking capacity among patients with intermittent claudication who underwent unsupervised clinical treatment, observing whether sustained treatment would increase or decrease maximum walking distance, whether after 6 months there was a change in the maximum distance, and whether abstinence from smoking and well-conducted walking exercise had independent effects on the outcome.
METHODS: Five hundred patients with intermittent claudication were surveyed in a prospective, nonrandomized, and uncontrolled study. Maximum walking distance and treatment compliance over time were analyzed.
RESULTS: Nonsmoking patients who walked achieved a mean increase during the first 6 months of 33.70 m/mo and a mean increase thereafter of 4.24 m/mo. Smokers who walked achieved an increase during the first 6 months only (mean, 42.92 m/mo). Patients who did not practice physical training exhibited no effect (smokers) or negligible effect (nonsmokers) from the treatment (mean, 7.58 m/mo).
CONCLUSIONS: Patients who adhered to physical training exhibited a significant increase in maximum walking distance during the first 6 months of treatment only. Patients who did not practice physical training exhibited no effect (smokers) or negligible effect (ex-smokers) from the treatment.

Entities:  

Mesh:

Year:  2003        PMID: 14581248     DOI: 10.1001/archinte.163.19.2296

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

Review 1.  Naftidrofuryl: a review of its use in the treatment of intermittent claudication.

Authors:  David R Goldsmith; Keri Wellington
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  Barriers to physical activity in patients with intermittent claudication.

Authors:  João Paulo Barbosa; Breno Quintella Farah; Marcel Chehuen; Gabriel Grizzo Cucato; José Cazuza Farias Júnior; Nelson Wolosker; Cláudia Lúcia Forjaz; Andrew W Gardner; Raphael Mendes Ritti-Dias
Journal:  Int J Behav Med       Date:  2015-02

3.  The progression rate of peripheral arterial disease in patients with intermittent claudication: a systematic review.

Authors:  A Mizzi; K Cassar; C Bowen; C Formosa
Journal:  J Foot Ankle Res       Date:  2019-08-06       Impact factor: 2.303

4.  Remote ischemic preconditioning in patients with intermittent claudication.

Authors:  Glauco Fernandes Saes; Antonio Eduardo Zerati; Nelson Wolosker; Luciana Ragazzo; Ruben Miguel Ayzin Rosoky; Raphael Mendes Ritti-Dias; Gabriel Grizzo Cucato; Marcelo Chehuen; Breno Quintella Farah; Pedro Puech-Leão
Journal:  Clinics (Sao Paulo)       Date:  2013-04       Impact factor: 2.365

5.  Eccentric strength and endurance in patients with unilateral intermittent claudication.

Authors:  Márcio Basyches; Nelson Wolosker; Raphael Mendes Ritti-Dias; Lucas Caseri Câmara; Pedro Puech-Leão; Linamara Rizzo Battistella
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

6.  Effect of Repeated Remote Ischemic Preconditioning on Peripheral Arterial Disease in Patients Suffering from Intermittent Claudication.

Authors:  Mehmet Balin; Tarık Kıvrak
Journal:  Cardiovasc Ther       Date:  2019-12-10       Impact factor: 3.023

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.